Bovie Medical Corporation Announces Appointment of Tara H. Semb as Chief Financial Officer
December 17 2018 - 7:30AM
Business Wire
Bovie Medical Corporation (NYSE:BVX) (the “Company”), a
maker of medical devices and supplies and the developer of
J-Plasma®, a patented surgical product marketed and sold under the
Renuvion® Cosmetic Technology brand in the cosmetic surgery market,
today announced the appointment of Tara H. Semb as Chief Financial
Officer, effective January 2, 2019.
“I am pleased to announce the appointment of Tara Semb, who
joins the executive leadership team at Bovie Medical with a strong
background in financial and operational business process and
internal controls,” said Charlie Goodwin, President and Chief
Executive Officer. “Ms. Semb’s career history includes executive
level experience as the Chief Financial Officer for a rapidly
growing company in the consumer market, and she has also held
senior positions on the finance team at a large, diversified global
manufacturing company with significant commercial scale and
profitability. I look forward to working closely with her as we
continue to position Bovie Medical for its next stage of
growth.”
“Bovie Medical is an impressive organization with a compelling
growth opportunity in the Cosmetic Surgery Market,” said Tara Semb.
“I am excited to join the Company at a time that I believe
represents an important inflection point in its history and look
forward to partnering with Charlie and the rest of the executive
leadership team.”
Prior to joining Bovie Medical, Ms. Semb was the Chief Financial
Officer for AVAIL Vapor LLC, a manufacturer and retailer of
e-liquid for use in electronic vapor devices, from 2015 until 2018.
Ms. Semb previously worked for Amsted Industries, a diversified
global manufacturer of industrial components, in multiple positions
of increasing responsibility from 2006 until 2015, culminating in
her promotion to Director of Finance for the company’s rail
bearings division in 2013. Before joining Amsted Industries as
Director of Internal Audit in 2006, she held financial and
operational roles at Blyth Industries, a manufacturer and seller of
candles and home fragrance products, and Anixter International, a
global distributor of network & security solutions. She began
her career in 1991 as an auditor at Price Waterhouse.
Ms. Semb holds a Bachelor of Science degree in Accounting from
the University of Illinois, as well as an MBA from Washington
University in St. Louis. She is a Certified Public Accountant
(CPA).
About Bovie Medical
Corporation:
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma® (marketed and
sold under the Renuvion™ Cosmetic Technology brand in the cosmetic
surgery market), a patented plasma-based surgical product for
cutting, coagulation and ablation of soft tissue. J-Plasma
technology utilizes a helium ionization process to produce a
stable, focused beam of plasma that provides surgeons with greater
precision, and minimal invasiveness. The new J-Plasma
handpieces with Cool-Coag™ technology deliver the precision of
helium plasma energy, the power of traditional monopolar
coagulation and the efficiency of plasma beam coagulation -
enabling thin-layer ablation and dissection and fast coagulation
with a single instrument, minimizing instrument exchange and
allowing a surgeon to focus on their patient and their procedures.
With Cool-Coag technology, the new J-Plasma handpieces can deliver
three distinctly different energy modalities - further increasing
the utility and versatility of the system. The Company also
leverages its expertise through original equipment manufacturing
(OEM) agreements with other medical device manufacturers. For
further information about the Company and its products, please
refer to the Bovie Medical Corporation website
at www.boviemedical.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
Forward-looking information is subject to certain risks, trends
and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the Company’s ability to control or predict. Important factors that
may cause actual results to differ materially and that could impact
the Company and the statements contained in this release can be
found in the Company’s filings with the Securities and Exchange
Commission including the Company’s Report on Form 10-K for the year
ended December 31, 2017 and subsequent Form 10-Q filings. For
forward-looking statements in this release, the Company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181217005105/en/
Investor Relations
Contact:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino,
CFA443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
Historical Stock Chart
From Apr 2024 to May 2024
Bovie (AMEX:BVX)
Historical Stock Chart
From May 2023 to May 2024